NCT06947460View on ClinicalTrials.gov

CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 18, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

July 31, 2026

Conditions
Refractory Lupus NephritisSystemic SclerosisPrimary Sjogren's Syndrome Combined With Pulmonary Hypertension
Interventions
DRUG

CD19-BCMA CAR-T cells infusion

Approximately 3-5 days prior to CD19-BCMA CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.

Trial Locations (1)

102200

RECRUITING

北京高博医院, Beijing

All Listed Sponsors
lead

Beijing GoBroad Hospital

OTHER